Research Paper Volume 16, Issue 8 pp 7188—7216

Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer


Figure 9. The relationship between TPX2 and PD-L1 in BRCA. (A) TIMER database illustrating the relationship between TPX2 and CD274 (PD-L1) in four BC subtypes. (B) RT-QPCR experiment illustrating the gene relationship between TPX2 and PD-L1. (C) Molecular docking simulating the amino acid interaction between TPX2 and PD-L1. (D) Flow cytometry illustrating the protein relationship between TXP2 and PD-L1. (E) Immunohistochemistry detecting the protein level of TPX2 and PD-L1 from tissue microarray. Scar bar: 100 μm. ***P < 0.001.